Cytodyn Inc (CYDY)

[pearsby09]

I still think if we get compelling Adjunct Data, that may trigger Off label, more proactive use of PRO 140. Not just within the Adjunct indication, but additional Off label use. For instance, Sub Cutaneous injections right out of the gate if CCR5 T Cell entry inhibitor antagonist upon verifiable diagnosis. Why not give the patients a some what prophylactic week one post diagnosis head start as we wait for HAART regimen. Get the T cells primed (Naive) with PRO 140 prior to HAART regimen. Hopefully, only half of the 4 toxic pills will be needed to sustain viral load suppression. Yes, with Adjunct, creativity with PRO 140 will be adoptive proactively..off label slightly perhaps, or maybe even more aggressively. Once these physicians get any kind of green light from an FDA approval they will use their proscribing talents to get started before Mono is completed. Of course, Adjunct must hit the primary and secondary end points and safety, compliance, convenience, lack of toxicity will open more gates (no pun intended) prior to the formal completion and approval of Mono. Of course when /if Mono therapy is validated 20 dollars per share...Boom! However, that is 18 months out minimum..unless BO or AA approval based on extremely strong interim readouts, following..Hopefully a successful Adjunct. This is a lethal unmet disease state. Fast Tract and Cure act in place. GLTA